In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of the catalysts highlighted in our Q3 2017 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Q4 2017.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.


Meddevicetracker Q4 2017 Outlook Report

Separately, Biomedtracker’s sister product, Meddevicetracker has published a concurrent report on 9 device catalysts expected to occur in Q4 2017, along with an overview of selected presentations from the upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference. This report can be downloaded for free here.

For more information on Meddevicetracker, visit its website www.meddevicetracker.com.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.